Fulgent's FID-007 Shows 61.9% Response Rate in Head and Neck Cancer Trial

Event summary

  • Fulgent Genetics presented updated Phase 2 trial data for FID-007 in combination with cetuximab at ASCO 2026, showing a 61.9% objective response rate in recurrent/metastatic head and neck squamous cell carcinoma (HNSCC).
  • The trial demonstrated a median progression-free survival of 6.7 months, median duration of response of 7.4 months, and one-year overall survival of 63.4%.
  • The study included 50 patients as of the April 16, 2026 data cutoff, with activity observed in both HPV-related and -unrelated HNSCC.
  • Fulgent plans to initiate a Phase 3 study for FID-007 based on these preliminary results.

The big picture

Fulgent's updated data for FID-007 represents a significant step in addressing the unmet need for second-line therapies in recurrent/metastatic HNSCC. The strong response rate positions Fulgent competitively in oncology, though it must now demonstrate consistency in larger trials. The company's shift from diagnostics to precision medicine is further validated by this clinical progress.

What we're watching

Clinical Validation
Whether FID-007 can maintain this response rate in larger, Phase 3 trials and gain regulatory approval.
Competitive Positioning
How Fulgent positions FID-007 against existing second-line therapies for HNSCC in the market.
Development Timeline
The pace at which Fulgent advances FID-007 through Phase 3 trials and potential commercialization.

Related topics

Biotechnology